Asset profile
CNM-Au8
Other
Evidence outlook · registrational
Amyotrophic Lateral Sclerosis: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-07.
Also in development:Multiple Sclerosis · Phase 2Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
108 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 108 same-indication; 76 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CNM-Au8: this drug | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Diroximel Fumarate (Vumerity) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| DRF | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Fampridine (Ampyra / Fampyra) | Approved | Small molecule | Potassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family) | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) |
…and 93 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
July 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.